The accelerated KT-621 Phase 2b readout to year-end 2026 is the primary catalyst. Traders should monitor the data release closely; positive results could drive a re-rating given the large TAM in Type 2 inflammation. Partnership milestones provide near-term cash but pipeline data is the key value driver. Watch for KT-579 Phase 1 data in Q4 2026.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $105.48entry
- T+1 · 3mo ago +0.88%α +1.04% · $106.41
- T+5 · 3mo ago +8.11%α +7.76% · $114.03
- T+20 · 3mo ago +12.47%α +13.07% · $118.63
- T+60 · 19d ago +14.50%α +14.31% · $120.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kymera Therapeutics reported Q2 2026 collaboration revenue of $65.0M (well above $32.8M consensus) and EPS of -$0.62 (beating -$0.74 consensus). The key catalyst is the completion of enrollment in the KT-621 Phase 2b AD trial nearly six months ahead of schedule, pulling forward topline data to year-end 2026, along with $65M in milestone payments from Gilead and Sanofi. The company ended the quarter with $1.5B cash, providing runway into 2029.
Key Financial Metrics
Key Facts
- Collaboration revenue $65.0M vs consensus $32.8M (beat), driven by $45M Gilead option and $20M Sanofi milestone
- EPS -$0.62 vs consensus -$0.74 (16.0% beat)
- KT-621 BROADEN2 Phase 2b AD trial enrollment completed ~6 months ahead of schedule; data readout accelerated to year-end 2026
- KT-621 Phase 3 trials in AD planned to initiate by mid-2027
- KT-579 (IRF5) Phase 1 data expected in Q4 2026; Phase 1b lupus trial planned
- Sanofi initiated Phase 1 for KT-485 (IRAK4), triggering a $20M milestone
- Cash position: $1.5B as of June 30, 2026, providing runway into 2029
- Net loss improved to $61.2M (from $76.6M in Q2 2025)
- New CMO appointed (Terence Rooney) and new Chairman (Felix J. Baker)
Financial Impact
Significant revenue beat driven by $65M in non-recurring milestones; net loss improved 20% YoY; cash slightly down but ample runway
Risk Factors
- KT-621 Phase 2b data may fail to meet efficacy or safety endpoints, resetting timelines
- Non-recurring milestone revenue creates lumpy financials; operating expenses continue to rise (R&D +52% YoY)
- Execution risk on Phase 3 initiation and multiple parallel trials
- Competition from approved biologics and other oral agents in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-333834 |
| Document: kymr-20260805.htm | 0001193125-26-333834 |
| Document: 0001193125-26-333834-index-headers.html | 0001193125-26-333834 |
| Document: 0001193125-26-333834-index.html | 0001193125-26-333834 |
| Document: 0001193125-26-333834.txt | 0001193125-26-333834 |
| 8-K Data (Synthetic) | 0001193125-26-333834 |
Track record
37 reports on KYMR
6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 8 of 13 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Viewing Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers